NO20004785D0 - Preparater for beskyttelse av PEG-interferon-<alfa>- konjugater - Google Patents

Preparater for beskyttelse av PEG-interferon-<alfa>- konjugater

Info

Publication number
NO20004785D0
NO20004785D0 NO20004785A NO20004785A NO20004785D0 NO 20004785 D0 NO20004785 D0 NO 20004785D0 NO 20004785 A NO20004785 A NO 20004785A NO 20004785 A NO20004785 A NO 20004785A NO 20004785 D0 NO20004785 D0 NO 20004785D0
Authority
NO
Norway
Prior art keywords
alfa
conjugates
interferon
peg
preparations
Prior art date
Application number
NO20004785A
Other languages
English (en)
Other versions
NO20004785L (no
NO329916B1 (no
Inventor
Douglas F Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004785(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20004785L publication Critical patent/NO20004785L/no
Publication of NO20004785D0 publication Critical patent/NO20004785D0/no
Publication of NO329916B1 publication Critical patent/NO329916B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
NO20004785A 1998-03-26 2000-09-25 Vandig formulering omfattende PEG-interferon-¿-konjugater, fremgangsmate for frysetorking av formuleringen, frysetorret pulver og artikkel omfattende pulveret NO329916B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4890798A 1998-03-26 1998-03-26
PCT/US1999/004268 WO1999048535A1 (en) 1998-03-26 1999-03-24 Formulations for protection of peg-interferon alpha conjugates

Publications (3)

Publication Number Publication Date
NO20004785L NO20004785L (no) 2000-09-25
NO20004785D0 true NO20004785D0 (no) 2000-09-25
NO329916B1 NO329916B1 (no) 2011-01-24

Family

ID=21957085

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004785A NO329916B1 (no) 1998-03-26 2000-09-25 Vandig formulering omfattende PEG-interferon-¿-konjugater, fremgangsmate for frysetorking av formuleringen, frysetorret pulver og artikkel omfattende pulveret

Country Status (26)

Country Link
EP (1) EP1066059B1 (no)
JP (3) JP3643034B2 (no)
KR (1) KR100420642B1 (no)
CN (1) CN1191863C (no)
AR (1) AR014772A1 (no)
AT (1) ATE297761T1 (no)
AU (1) AU754002B2 (no)
BR (1) BR9909087A (no)
CA (1) CA2324467C (no)
CO (1) CO5080738A1 (no)
CZ (1) CZ302005B6 (no)
DE (1) DE69925820T2 (no)
ES (1) ES2241272T3 (no)
HK (1) HK1029754A1 (no)
HU (1) HU228877B1 (no)
ID (1) ID28470A (no)
IL (2) IL138221A0 (no)
MY (1) MY119227A (no)
NO (1) NO329916B1 (no)
NZ (1) NZ506631A (no)
PE (1) PE20000338A1 (no)
PL (1) PL193286B1 (no)
PT (1) PT1066059E (no)
SK (1) SK285284B6 (no)
TW (2) TWI243057B (no)
WO (1) WO1999048535A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
JP4721488B2 (ja) * 1999-04-08 2011-07-13 シェーリング コーポレイション 腎細胞ガン処置
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US20020009428A1 (en) * 2000-01-24 2002-01-24 Zaknoen Sara L. Combination therapy for cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
DK1478339T3 (da) 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
WO2009080699A2 (en) 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
JP2015535238A (ja) * 2012-10-26 2015-12-10 ルピン・リミテッドLupin Limited ペグインターフェロンα−2bの安定な医薬組成物
KR101736870B1 (ko) 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN112358541B (zh) * 2020-11-25 2022-04-01 广州迪澳医疗科技有限公司 一种重组人γ-干扰素的冻干保护剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates

Also Published As

Publication number Publication date
HU228877B1 (en) 2013-06-28
DE69925820D1 (de) 2005-07-21
WO1999048535A1 (en) 1999-09-30
JP2005104985A (ja) 2005-04-21
IL138221A (en) 2007-12-03
CA2324467C (en) 2002-11-05
PE20000338A1 (es) 2000-05-16
KR100420642B1 (ko) 2004-03-02
BR9909087A (pt) 2000-12-05
AR014772A1 (es) 2001-03-28
AU754002B2 (en) 2002-10-31
PL345568A1 (en) 2001-12-17
AU3181299A (en) 1999-10-18
CZ302005B6 (cs) 2010-09-01
MY119227A (en) 2005-04-30
JP2003221345A (ja) 2003-08-05
KR20010034654A (ko) 2001-04-25
HUP0101749A3 (en) 2001-12-28
PT1066059E (pt) 2005-10-31
NO20004785L (no) 2000-09-25
JP4580744B2 (ja) 2010-11-17
SK285284B6 (sk) 2006-10-05
SK14262000A3 (sk) 2001-04-09
HK1029754A1 (en) 2001-04-12
ES2241272T3 (es) 2005-10-16
NZ506631A (en) 2003-03-28
DE69925820T2 (de) 2006-05-18
CN1295484A (zh) 2001-05-16
NO329916B1 (no) 2011-01-24
CA2324467A1 (en) 1999-09-30
ID28470A (id) 2001-05-24
IL138221A0 (en) 2001-10-31
TWI250024B (en) 2006-03-01
PL193286B1 (pl) 2007-01-31
JP2002507583A (ja) 2002-03-12
CN1191863C (zh) 2005-03-09
EP1066059B1 (en) 2005-06-15
TW200536557A (en) 2005-11-16
EP1066059A1 (en) 2001-01-10
TWI243057B (en) 2005-11-11
JP3643034B2 (ja) 2005-04-27
HUP0101749A2 (hu) 2001-11-28
CO5080738A1 (es) 2001-09-25
CZ20003315A3 (cs) 2001-04-11
ATE297761T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
DE69900634D1 (de) Shampoozusammensetzungen
FI981436A0 (fi) Häiriösuoja
NO2009003I1 (no) Etravirin
DE69918109D1 (de) Haarwaschmittel
IS2325B (is) Örgerðar samsetningar epleróns
DE69937195D1 (de) Siloxysilicate enthaltende stabilisierten shampoo
FR09C0030I2 (fr) Composes thrombopoietiques
NO20004785L (no) Preparater for beskyttelse av PEG-interferon-&lt;alfa&gt;- konjugater
DE59901642D1 (de) Sonnenschutzmittel
DE69913681T2 (de) Schutzanordnung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ATE246494T1 (de) Brausezubereitungen
NO991088L (no) Selvlåsende kopling
DE29802228U1 (de) Lagerschild
FI982378A0 (fi) Järjestely kohteen tutkimiseen
FR2790805B1 (fr) Ensemble d&#39;accouplement
NO994427D0 (no) Kopling
DE69904192D1 (de) Hitzeschilde
ATE243218T1 (de) 2&#39;&#39;-deoxyhygromycinderivate
NO992344D0 (no) Kopling
ID23006A (id) 13-dihidro-3&#39; aziridino antrasiklina
FI3524U1 (fi) Yhdistelmäkoura
DE29804761U1 (de) Faltenbalg
NO992345L (no) Kopling
IT1304635B1 (it) Mezzi di raccordo

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MK1K Patent expired